deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT01543763

Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors

Phase I Study to Evaluate the Tolerability, Efficacy, and Safety of Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors

Sponsor: GlaxoSmithKline Research and Education Foundation for Cardiovascular Disease

Conditions Metastatic Solid Tumors
Interventions PZP115891, PCI-24781
Updated 17 times since 2017 Last updated: Mar 19, 2025 Started: Jun 25, 2012 Primary completion: Jan 31, 2024 Completion: Dec 31, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01543763, this PHASE1 trial focuses on Metastatic Solid Tumors and remains completed. Sponsored by GlaxoSmithKline Research and Education Foundation for Cardiovascular Disease, it has been updated 17 times since 2012, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Sep 2017 · 7 months · monthly snapshot~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshot~Jun 2018 – ~Feb 2020 · 20 months · monthly snapshot~Feb 2020 – ~Jun 2020 · 4 months · monthly snapshot~Jun 2020 – ~Nov 2020 · 5 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Sep 2022 · 12 months · monthly snapshot~Sep 2022 – ~Sep 2023 · 12 months · monthly snapshot~Sep 2023 – ~Feb 2024 · 5 months · monthly snapshot~Feb 2024 – ~Mar 2024 · 29 days · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshot~Apr 2025 – ~Jun 2025 · 2 months · monthly snapshot~Jun 2025 – present · 13 months · monthly snapshot

Change History

17 versions recorded

  1. Jun 2025 — Present [monthly]

    Completed PHASE1

  2. Apr 2025 — Jun 2025 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  3. Sep 2024 — Apr 2025 [monthly]

    Active Not Recruiting PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1

  5. Mar 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

▶ Show 12 earlier versions

  1. Feb 2024 — Mar 2024 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  2. Sep 2023 — Feb 2024 [monthly]

    Recruiting PHASE1

  3. Sep 2022 — Sep 2023 [monthly]

    Recruiting PHASE1

  4. Sep 2021 — Sep 2022 [monthly]

    Recruiting PHASE1

  5. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

  6. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  7. Jun 2020 — Nov 2020 [monthly]

    Recruiting PHASE1

    Status: Unknown Status → Recruiting

  8. Feb 2020 — Jun 2020 [monthly]

    Unknown Status PHASE1

    Status: Active Not Recruiting → Unknown Status

  9. Jun 2018 — Feb 2020 [monthly]

    Active Not Recruiting PHASE1

  10. Sep 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

    Status: Unknown Status → Active Not Recruiting

  11. Feb 2017 — Sep 2017 [monthly]

    Unknown Status PHASE1

  12. Jan 2017 — Feb 2017 [monthly]

    Unknown Status PHASE1

    First recorded

Jun 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline Research and Education Foundation for Cardiovascular Disease
  • Novartis
  • Pamela Munster
  • Pharmacyclics LLC.
  • Xynomic Pharmaceuticals, Inc.
Data source: University of California, San Francisco

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations